Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5209413 | 0.82 | MAPK9 (0.55) | MAPK9MAPK10PDE4BPDE10AMAPK8 | |
| SCHEMBL5214203 | 0.78 | MAPK9 (0.48) | MAPK9MAPK10PDE4BPDE10AMAPK8 | |
| SCHEMBL5214934 | 0.77 | EIF2AK2 (0.51) | EIF2AK2MAPK9MAPK10MAPK8CDK4 | |
| SCHEMBL5427918 | 0.77 | MAPK9 (0.52) | EIF2AK2MAPK9MAPK10PDE4BPDE10A | |
| SCHEMBL5220849 | 0.77 | EIF2AK2 (0.50) | EIF2AK2MAPK9MAPK10MAPK8 | |
| SCHEMBL1269420 | 0.76 | MAPK9 (0.56) | EIF2AK2MAPK9MAPK10PDE4BPDE10A | |
| SCHEMBL5210662 | 0.76 | MAPK9 (0.56) | MAPK9MAPK10PDE4BPDE10AMAPK8 | |
| SCHEMBL5430843 | 0.75 | MAPK9 (0.59) | EIF2AK2MAPK9MAPK10PDE4BPDE10A | |
| SCHEMBL5439136 | 0.75 | MAPK9 (0.74) | MKNK2MAPK9MAPK10PDE4BPDE10A | |
| SCHEMBL5725747 | 0.75 | EIF2AK2 (0.48) | EIF2AK2MAPK9MAPK10PDE4BPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | QDPR, DPYD, ENTPD5 | EIF2AK2 57/4885MKNK2 1437/4885MAPK9 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.